Upside, Downside Movers in the Morning
Upside
- TNON +122.0% (USPTO notice of allowance for SI-joint stabilization patent; >11M premarket shares)
- MRNA +106.0%, MRK +8.5% (Phase 3 personalized mRNA melanoma vaccine + Keytruda met the primary recurrence-free-survival endpoint and key metastasis endpoint; first positive late-stage result for an individualized mRNA cancer vaccine)
- YJ +57.5% (very high-volume speculative move ahead of H1 results due tomorrow; no fresh company-specific catalyst identified)
- BIVI +39.0% (sharp high-volume rebound after Tuesday’s –18% selloff; no new fundamental catalyst identified)
- RCON +24.5% (rebound after prior-session weakness despite the recently announced $100M ATM; no new positive catalyst identified)
- EHGO +24.0% (12M+ share momentum move; no material fresh company-specific catalyst identified)
- GOVX +18.5%, BNTX +15.0% (vaccine/oncology sympathy after the MRNA/MRK Phase 3 breakthrough materially improves sentiment toward vaccine-platform oncology)
- CAST +17.5% (continuation of the high-volume streaming/media re-rating after recent platform/distribution expansion news)
- TGL +10.5% ($2M software-enhancement agreement disclosed in an 8-K)
- MSS +9.5% (high-volume continuation around the recent SEC ownership filing; no additional fundamental catalyst identified)
- EL +9.0% (Q4 EPS $0.39 vs $0.32 expected and revenue $3.63B vs $3.55B; FY profit outlook came in above Street expectations)
- KC +8.5% (Q2 beat as revenue grew 30.8% YoY and AI-cloud billings surged 82%, strengthening the AI-cloud growth read-through)
- TEM +6.5% (Q2 revenue beat, loss narrowed and 2026 sales guidance raised as diagnostics/data growth ran ahead of expectations)
- ODFL +5.0% (large-cap transport mover with no material fresh company-specific catalyst identified)
- DUOL +4.0% (rally after an inadvertent disclosure of the latest DAU growth rate gave investors an early read on user momentum)
Downside
- PFSA –43.5% (violent reversal after Tuesday’s +507% squeeze; >200K premarket shares and no new fundamental catalyst supporting the prior spike)
- WYFI –24.0% ($250M convertible-senior-notes offering, with an additional purchaser option, raises dilution/financing-overhang concerns)
- UCL –21.5% (high-volume selloff with no material fresh company-specific catalyst identified)
- SGLY –20.0% ($1.8M registered direct offering plus broader disclosed share/warrant dilution)
- TPET –18.5% (1-for-9 reverse stock split announced to maintain exchange compliance)
- RIME –18.0% (nearly 10M premarket shares in a momentum unwind; no fresh fundamental catalyst identified)
- WETO –17.0% (heavy speculative selling on meaningful premarket turnover; no clear fresh catalyst identified)
- LZB –16.5% (Q1 adjusted EPS $0.43 vs $0.49 expected, revenue ~$476M well below Street, and Q2 sales guidance $500–520M vs ~$537M consensus)
- MRCY –9.5% (Q4 revenue beat but adjusted EPS $0.37 missed ~$0.39 expectations, disappointing after the stock’s strong YTD run)
- ESS –9.0% (abnormally large isolated REIT move; no new material company filing or fundamental catalyst identified this morning)
- TJX –3.5% (Q2 headline beat and FY EPS raised, but Marmaxx comps were below management expectations and the FY comp outlook was not raised; tariff refunds also boosted reported profitability)
- LOW –3.0% (EPS $4.40 beat $4.23, but revenue $26.0B missed ~$26.16B and FY comparable-sales expectations were cut to roughly flat as discretionary demand remains cautious)
- HPE –3.5%, ORCL –2.5%, SMCI –2.0%, GLW –2.0%, MRVL –2.0% (continued AI/technology de-risking after Tuesday’s hardware/chip rout as elevated long yields keep pressure on long-duration growth valuations)
